← Leaderboards
Jennifer Nixon
Vanderbilt University Medical Center
$2,776,885
Attributed
$2,776,885
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2018–19$2M$1.5M$1M$500K$0
'18
'19
Funding mix
By agency
NIH$2,776,885 · 1
By mechanism
N01$2,776,885 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Debra L Friedman$19,684,821
- Clarence Buddy Creech$64,037,457
- Richard M Peek$40,629,039
- Linda J Hood$4,647,742
- Michael Rutledge Debaun$40,846,229
Others in their field
Other Emerging Leaders on “Bacterial Drug Resistance”
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Bruce Blough · Research Triangle Institute$19,637,160
- Terry Roemer · Prokaryotics, Inc.$13,757,579
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$11,832,144
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$11,098,301
- Jeanette Coffin · Midwest Research Institute$10,204,323
Research focus
Bacterial Drug ResistanceChildCombatCommunicable DiseasesCommunitiesConduct Clinical TrialsContractsDesignEvaluationNamed GroupOutpatientsPediatricsPhase Iv Clinical TrialsPhase Iv TrialPneumoniaProgramsResourcesStreptococcus PneumoniaeTherapeutic Community TechniqueVaccines
Grant awards (2)
Vaccine and Treatment Evaluation Unit: Phase IV Clinical Trial to Evaluate Therapeutics for Community Acquired Pneumonia in Children$1,100,144
N01 · FY2019 · AI · contact PI
Vaccine and Treatment Evaluation Unit: Phase IV Clinical Trial to Evaluate Therapeutics for Community Acquired Pneumonia in Children$1,676,741
N01 · FY2018 · AI · contact PI